Batch Records and Janoshik COAs — Verify Every Remy Peptides Lot

Key Facts

What We Supply

Remy Peptides supplies research-grade peptides formulated for in-vitro laboratory applications, organised around a retatrutide-led catalogue. The flagship line is Retatrutide (LY-3437943)—a synthetic peptide that simultaneously engages GLP-1, GIP, and glucagon receptor pathways, and one of the most studied next-generation compounds in metabolic research—offered in prefilled-pen and lyophilized-vial formats. The active UAE-facing format list is maintained on the Retatrutide UAE formats page.

The catalogue extends well beyond the metabolic flagship into six research categories. Retatrutide and GLOW ship as prefilled pens in a pH-balanced, bacteriostatic solution that removes the reconstitution step; the remainder of the line ships as lyophilized research vials, with bacteriostatic water for reconstitution sold separately at AED 80 per 11 mL ZPHC unit.

Across the catalogue, each compound is manufactured under controlled GMP-adjacent conditions and undergoes a full analytical workup before release—retatrutide batches are independently HPLC-verified by Janoshik Analytical, and non-retatrutide vials are documented at >99% HPLC purity.

All compounds are supplied strictly for in-vitro laboratory research purposes and are not intended, marketed, or approved for human or veterinary diagnostic or therapeutic use in any jurisdiction.

Quality Assurance

Independent verification is the cornerstone of the Remy Peptides quality framework. Each published Retatrutide batch is submitted to Janoshik Analytical—a widely recognized third-party laboratory specializing in peptide and pharmaceutical-grade compound analysis—for full HPLC purity testing: 30mg pen RETP002 at 99.262%, 20mg pen RET-20-C-2604-001 at 99.841%, retatrutide 20mg (pen line) RET-20-V-2604-001 at 99.741%, and 40mg vial RT-40-V-001 at 99.692% (sterility-tested). The PT-141 20mg pen batch PT20P-001 is published at 99.703%. The 10mg pen COA is pending. Only batches that meet or exceed the ≥99.2% purity threshold are approved for distribution. Published Certificates of Analysis are available on-site for every released lot number. Non-retatrutide research vials—across the tissue-repair, copper, mitochondrial, growth-hormone-secretagogue, and other targeted categories—are documented at >99% HPLC purity, with lot-specific COAs available on request. For a plain-English explanation of HPLC purity, assay, endotoxin, TFA, and heavy-metals fields, see the Peptide COA Guide. Full batch-level proof for the active products lives in the COA Library; for the SEO/AEO explainer layer with methodology + FAQ per product, see the Lab Results hub.

All orders are shipped via cold-chain courier, in insulated cold-chain packaging intended to maintain product stability between 2–8°C. Same-day delivery is available for Dubai orders placed before 4 PM, with most arriving within 4 hours.

This approach—third-party analytical verification, published COAs, and cold-chain shipping—is designed to give researchers full confidence that the compound arriving at their bench matches the specification printed on the label.

Evidence Pack

1. 01
   Batch proof and purity route

   Batch-level proof lives in the COA archive, with a field-by-field explanation in the Peptide COA Guide. To check a report against the lab yourself, follow the Janoshik verification guide. The flagship reference is batch RETP002, independently tested by Janoshik Analytical at 99.262% HPLC purity (task 86428, key 97SPA7G1BJUL).

2. 02
   Authorship and editorial oversight

   Fact-pattern pages are reviewed by the Remy Peptides Editorial Team, with process rules documented on the editorial policy page.

3. 03
   Verification and contact integrity

   The official website, email, and any approved public channels are maintained on Contact Verification. If a contact route is missing from that page, it is not an approved trust signal for this brand record.

4. 04
   Compliance and destination review

   Research-only language, source hierarchy, and destination-country qualification rules are anchored in Research Standards. That page governs how GCC and global enquiries are screened before dispatch.